Mettler-Toledo International (MTD)

Earnings Preview — 2Q 2026

Upcoming Earnings Date: July 31, 2026 | Prepared: July 29, 2026 | Reporting Period: 2Q 2026 (quarter ending June 30, 2026)

1. Earnings Preview

Key Takeaway: The setup into 2Q 2026 is mixed — consensus sits modestly below management's guidance midpoint on EPS, creating a low bar, but the stock has already rallied ~5% since the Q1 print, meaning any guidance disappointment (particularly on 2H cadence) could be punished. The single biggest swing factor is whether China industrial momentum and bioprocessing strength are enough to offset continued Western market softness.

Heading into the 2Q 2026 print, the bar for MTD appears manageable: management guided 2Q adjusted EPS to $10.70–$10.85 (midpoint $10.775), while current consensus sits at ~$10.81 — essentially in line with guidance, leaving limited room for a meaningful beat unless volume or pricing surprises to the upside. Management's tone on the Q1 call was cautiously constructive — they raised full-year EPS guidance to $46.30–$46.95 while acknowledging macro uncertainty, Middle East conflict-driven energy cost inflation, and customer delays in Western markets. Estimate revisions have drifted modestly lower since the Q1 print (from ~$10.77 to ~$10.81 on a net basis), suggesting the Street has largely absorbed the guidance and is not pricing in a significant beat. The stock has recovered sharply from its post-Q1 gap-down (from ~$1,319 pre-print to a low of ~$1,025 before recovering to ~$1,388 as of July 28), implying the market has re-rated the stock higher on improving peer read-throughs (TMO's strong Q2 beat) and China optimism — a dynamic that raises the bar for the actual print. The key wildcard is whether Danaher's cautious 3Q bioprocessing commentary (>$100M of revenue pushed out of the year) creates a read-through headwind for MTD's biopharma segment, even as Thermo Fisher's strong Q2 organic growth of ~5% (200bps above consensus) signals broad-based life science tools recovery.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is essentially in line with management's guidance midpoint on both revenue and EPS, creating a low-to-neutral bar. Organic growth is the bigger swing factor — consensus at ~2.0% organic for 2Q implies modest improvement from Q1's 1.5% organic, and any upside from China industrial or bioprocessing acceleration could drive a beat.

Table 1 — 2Q 2026 Current Quarter Snapshot (All Key KPIs)

Sources: Visible Alpha Consensus and Actuals Data; MTD Q1 2026 Earnings Release and Transcript (May 7–8, 2026). LC = local currency. SD = single digit. Acq. = acquisition contribution.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

Diluted EPS — Operating ($)

Net Sales ($M)

Pattern: MTD has beaten consensus on both EPS and revenue in every reported quarter over the trailing 7 quarters, with EPS beats averaging ~4% and revenue beats averaging ~2%. This consistent beat pattern suggests management guides conservatively, but the stock's post-Q1 recovery already prices in some of this tendency.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance has not changed since the Q1 2026 earnings call (May 7–8, 2026). Management's tone was cautiously constructive — they raised full-year EPS guidance while flagging macro uncertainty, Middle East energy cost inflation, and customer delays. No post-earnings guidance revisions or 8-K updates have been issued.

Source: MTD Q1 2026 Earnings Release and Transcript (May 7–8, 2026); Visible Alpha Consensus Data.

Key management commentary since Q1 earnings: No material post-earnings guidance updates or 8-K filings have been issued. The May 13, 2026 8-K related to an executive compensation structure change (LTI target increases) and the May 11, 2026 8-K confirmed shareholder approval of all annual meeting proposals — neither contained guidance revisions. Management's last public commentary on the business remains the Q1 2026 earnings call.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates for 2Q 2026 EPS have drifted modestly lower since the Q1 print (from ~$10.77 post-print to ~$10.81 current — a slight uptick on net), while full-year estimates have moved up slightly, tracking the raised guidance. The gap between consensus and guidance midpoint is narrow on EPS, suggesting the Street has largely digested the Q1 guidance and is not pricing in a significant beat or miss.

Source: Visible Alpha Consensus and Actuals Data (as-of date: May 14, 2026 and July 29, 2026); MTD Q1 2026 Earnings Release and Transcript.

Commentary: Estimates are essentially flat since the Q1 print, tracking guidance closely. The slight uptick in organic growth consensus (from ~1.84% to ~2.03%) likely reflects improving peer read-throughs from TMO and DHR. Full-year EPS consensus at $46.72 sits near the upper half of the $46.30–$46.95 guidance range, implying the Street expects MTD to execute at or above the midpoint — consistent with the company's historical beat pattern.

5. Stock Performance

Key Takeaway: MTD's post-Q1 stock performance has been driven primarily by multiple re-expansion rather than estimate revisions (which were flat). The stock gapped down ~15% on the Q1 print (Q2 EPS guidance below consensus), then recovered sharply to new highs by late July, outperforming XLI and the S&P 500 since the earnings date — driven by improving peer read-throughs (TMO's strong Q2 beat) and China optimism.

Sector ETF: XLI (Industrial Select Sector SPDR ETF) is used as the sector benchmark. MTD is classified as an Industrial company (precision instruments / industrial automation), and XLI captures the broad industrial sector including automation, measurement, and process control companies that share MTD's end-market exposures. While MTD also has significant life science exposure, XLI is the most appropriate single-ETF benchmark given MTD's primary GICS classification.

MTD vs. XLI vs. S&P 500 — Indexed Performance Since Q1 2026 Earnings (May 7, 2026). Base = 100. MTD gapped down ~15% on the Q1 print before recovering sharply to +5.2% by July 28, outperforming XLI (+4.9%) and the S&P 500 (+1.3%). Source: Stock Price Data.

Performance Summary (May 7 → July 28, 2026):

• MTD: $1,319.29 → $1,388.38 = +5.2% (indexed from 100 to 105.2)
• XLI: $174.00 → $182.49 = +4.9% (indexed from 100 to 104.9)
• S&P 500 (SPY): $731.58 → $740.86 = +1.3% (indexed from 100 to 101.3)

Key events during the period:

• May 7–8, 2026 (Q1 Earnings): MTD gapped down ~15% (from $1,319 to ~$1,124) as Q2 EPS guidance came in below consensus despite the Q1 beat.
• May–June 2026: Gradual recovery as macro uncertainty eased and China industrial data improved.
• July 21, 2026 (DHR Earnings): Danaher's Q3 guidance miss caused a ~14% single-day decline in DHR; MTD dipped modestly but recovered quickly, suggesting the market viewed DHR's issues as company-specific.
• July 23, 2026 (TMO Earnings): Thermo Fisher's strong Q2 beat (EPS $6.03 vs. $5.72 consensus; organic growth +5%, ~200bps above consensus) drove TMO +10% and lifted MTD and the broader life science tools sector.

Valuation context: MTD currently trades at ~28x NTM P/E and ~21x NTM EV/EBITDA (vs. ~21x and ~19x three months ago), reflecting multiple re-expansion of ~6–9% over the past quarter. The stock's recovery to new highs ahead of the print raises the bar for the actual 2Q result.

6. Peer Commentary & Read-Through

Key Takeaway: Peer commentary since MTD's Q1 earnings is net positive for the 2Q 2026 setup. Thermo Fisher's strong Q2 beat signals broad-based life science tools recovery, and Danaher confirms mid-single digit China growth and strengthening pharma/biopharma demand. The key caution is Danaher's >$100M bioprocessing revenue push-out, which could create a modest headwind for MTD's biopharma segment, though underlying order trends remain healthy.

Note on scope: Only commentary from peers' most recent earnings calls (reporting on their own current quarter, which is 2Q 2026 for TMO and DHR) and conference presentations made after MTD's Q1 2026 earnings (May 7, 2026) are included. Prior-quarter results commentary is excluded.

6A. Thermo Fisher Scientific (TMO) — 2Q 2026 Earnings Call (July 23, 2026)

Read-Through Assessment: DIRECT & POSITIVE

TMO's 2Q 2026 results are the most directly relevant read-through for MTD. TMO reported EPS of $6.03 vs. $5.72 consensus and organic revenue growth of +5% (approximately 200bps above consensus), with management noting that "customer activity across our end markets continued to strengthen." TMO raised full-year organic growth guidance to ~4% (upper end of 3–4% range) and raised full-year EPS guidance to $24.93–$25.33 (+9–11% growth). The stock rose ~10% on the day, its largest intraday gain since October 2008.

Source: TMO 2Q 2026 Earnings Call Transcript (July 23, 2026).

6B. Danaher (DHR) — 2Q 2026 Earnings Call (July 21, 2026)

Read-Through Assessment: MIXED — POSITIVE ON DEMAND, CAUTIOUS ON BIOPROCESSING TIMING

DHR reported 2Q 2026 EPS of $1.94 vs. $1.84 consensus and revenue of $6.26B vs. $6.1B consensus, with operating margins of 27.1% vs. 26.6% consensus. The company raised full-year EPS guidance to $8.45–$8.60 from $8.35–$8.55. However, the stock fell ~14% (its worst day since 2001) as 3Q core revenue growth guidance of +2–3% fell well short of expectations, and the company narrowed full-year core revenue growth to 3–4% (anchoring to the low end). The key negative was >$100M of bioprocessing revenue pushed out of 2Q/3Q into next year due to customer timing.

Source: DHR 2Q 2026 Earnings Call Transcript (July 21, 2026); DHR 2Q 2026 Earnings Release (July 20, 2026).

6C. Bruker (BRKR) — Jefferies Global Healthcare Conference (June 4, 2026)

Read-Through Assessment: LIMITED — DIRECTIONALLY CONSISTENT

Bruker's CFO Gerald Herman presented at the Jefferies Global Healthcare Conference on June 4, 2026, providing forward-looking commentary on 2Q 2026 and FY 2026. BRKR is a smaller, more specialized peer (scientific instruments, mass spectrometry, NMR) with less direct overlap to MTD's core businesses, but some read-throughs are relevant.

Source: BRKR Jefferies Global Healthcare Conference Transcript (June 4, 2026).

6D. Agilent Technologies (A) — Jefferies Global Healthcare Conference (June 3, 2026)

Read-Through Assessment: LIMITED — DIRECTIONALLY POSITIVE ON REPLACEMENT CYCLE & CHINA STIMULUS

Agilent presented at the Jefferies Global Healthcare Conference on June 3, 2026. Agilent's primary businesses (chromatography, mass spectrometry, genomics) have limited direct overlap with MTD's core precision weighing and inspection businesses, but some themes are relevant.

Source: Agilent Jefferies Global Healthcare Conference Transcript (June 3, 2026).

Peer Read-Through Summary

7. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is Thermo Fisher's strong Q2 beat (July 23), which signals broad-based life science tools recovery and has driven MTD's stock to new post-Q1 highs. Danaher's Q3 guidance miss (July 21) is a secondary concern but appears company-specific rather than sector-wide.

• July 23, 2026 — TMO 2Q 2026 Earnings Beat: Thermo Fisher reported EPS of $6.03 vs. $5.72 consensus and organic growth of +5% (~200bps above consensus). Management raised full-year guidance and noted end markets "continue to strengthen." Stock rose ~10% on the day. Implication: Strongest positive read-through for MTD's 2Q print; signals broad-based life science tools recovery that should benefit MTD's lab and industrial segments.
• July 21, 2026 — DHR 2Q 2026 Earnings: Q3 Guidance Miss: Danaher beat 2Q estimates but guided 3Q core revenue growth to +2–3% (well below expectations) and pushed >$100M of bioprocessing revenue out of the year. Stock fell ~14%, its worst day since 2001. Implication: Modest negative read-through for MTD's biopharma segment, though DHR's issues appear related to large chromatography resin shipment timing rather than broad demand weakness. MTD's bioprocessing exposure is primarily instruments, not large consumable shipments.
• May 13, 2026 — MTD Executive Compensation Structure Change (8-K): Mettler-Toledo altered its executive compensation structure, increasing long-term incentive (LTI) targets. Implication: Signals management confidence in long-term business trajectory; higher LTI targets align executive incentives with sustained performance. Not a guidance event.
• May 11, 2026 — MTD Annual Meeting: All Proposals Approved (8-K): Shareholders approved all proposals at the annual meeting. Implication: Routine governance event; no material business implications.
• July 6, 2026 — MTD Announces 2Q 2026 Earnings Call (Press Release): Mettler-Toledo announced it will host its 2Q 2026 earnings conference call on July 31, 2026. Implication: Confirms earnings date; no guidance update included.
• May 1, 2026 — MTD Announces BofA Healthcare Conference Webcast: MTD announced a webcast presentation at the BofA Securities 2026 Healthcare Conference. No transcript or material guidance update available in the research context. Implication: Routine investor relations activity; no material new information identified.

8. Insider Transaction Activity

Key Takeaway: One insider transaction was identified for MTD in the period since the Q1 2026 earnings (May 7, 2026): a Form 144 notice of intended sale filed by Michael A. Kelly on July 28, 2026. This appears to be a planned sale (Form 144 is a notice of intended sale, typically associated with 10b5-1 plans or restricted stock). No open-market discretionary buys or sells (Form 4 codes P/S) were identified for MTD in the period. The absence of open-market buying is not unusual given the stock's recovery to near all-time highs.

Source: SEC Form 144 filing (July 28, 2026); SEC EDGAR.

Overall assessment: Nothing stands out as a meaningful insider signal. The single Form 144 notice is a routine planned sale and does not indicate discretionary bearish conviction. The absence of open-market buying is consistent with the stock trading near all-time highs. No Form 4 open-market purchases or sales (codes P/S) were identified for MTD in the period since Q1 earnings.